logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2020 — Advanced esophageal cancers: the added value of first-line immunotherapy

Pembrolizumab with chemo yielded better survival, response rates vs chemo with placebo.